Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 4/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312978 | 0.92 | CYP17A1 (0.41) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL314420 | 0.90 | CYP17A1 (0.40) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL312425 | 0.90 | CYP17A1 (0.40) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL2946274 | 0.89 | CYP17A1 (0.43) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL313156 | 0.89 | CYP17A1 (0.39) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL4024970 | 0.87 | CYP17A1 (0.44) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL4033375 | 0.85 | CYP17A1 (0.43) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL313034 | 0.85 | CYP17A1 (0.43) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL312882 | 0.85 | CYP17A1 (0.43) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 | |
| SCHEMBL4028443 | 0.84 | CYP17A1 (0.42) | CYP17A1CYP3A4ACSS2SIRT2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2275411-A2 | Reformatsky Reagent in Stable Form and Process for Producing the Same | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | CYP17A1 1/4885CYP3A4 136/4885RIPK1 475/4885 |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | CYP17A1 1/4885CYP3A4 136/4885RIPK1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.